The first and only Monoamine Oxidase Inhibitor patch for the treatment of Major Depressive Disorder in adults1
The first and only Monoamine Oxidase Inhibitor patch for the treatment of Major Depressive Disorder in adults1
The first and only Monoamine Oxidase Inhibitor patch for the treatment of Major Depressive Disorder in adults1
EMSAM (selegiline transdermal system) is a monoamine oxidase inhibitor (MAOI) indicated for the treatment of adults with major depressive disorder (MDD)
EMSAM (selegiline transdermal system) is a monoamine oxidase inhibitor (MAOI) indicated for the treatment of adults with major depressive disorder (MDD)
Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors.
EMSAM is contraindicated in patients less than 12 years of age because of an increased risk of hypertensive crisis.
Reference:
1. Emsam [prescribing information]. Morgantown, WV: Somerset Pharmaceuticals Inc.; 2020.
Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors.
EMSAM is contraindicated in patients less than 12 years of age because of an increased risk of hypertensive crisis.
EMSAM (selegiline transdermal system) is a monoamine oxidase inhibitor (MAOI) indicated for the treatment of adults with major depressive disorder (MDD)
EMSAM® is a registered trademark of Somerset Pharmaceuticals, Inc., a Viatris Company.
VIATRIS and the Viatris Logo are trademarks of Mylan Inc., a Viatris Company.
© 2021 Viatris Inc. All Rights Reserved. EMS-2021-0019 v2